Cellecta

Executive Summary

Cellecta is a privately held genomics company based in Mountain View, California, founded in 2006. The company provides a comprehensive suite of genomic products and services, including functional screening libraries, lentiviral constructs, clonal barcodes, and transcriptome and adaptive immune receptor profiling kits. These tools are essential for drug target identification, validation, and biomarker discovery, enabling researchers to identify genes that drive disease and therapeutic response. Cellecta’s offerings support a wide range of applications in oncology, immunology, and genetic medicine, positioning the company as a key enabler in the drug development ecosystem. Despite operating in a competitive landscape with players like Horizon Discovery and Dharmacon, Cellecta differentiates itself through its focus on pooled screening and custom library design, which are critical for modern functional genomics studies. The company is well-positioned to benefit from growing demand for genomic tools as pharmaceutical and biotech companies increasingly rely on CRISPR and RNAi-based screens to de-risk drug candidates. Cellecta’s expertise in lentiviral vector technology and high-throughput barcoding allows for robust in vivo and in vitro screening, which is becoming standard in preclinical research. While the company remains private and does not disclose financial details, its long-standing presence in the market suggests stability and a loyal customer base. Looking ahead, Cellecta may expand its portfolio to include single-cell multi-omics solutions or forge strategic partnerships with large pharma to co-develop screening platforms. However, without a clear pipeline of proprietary therapeutics, the company’s growth is tied to the broader demand for research tools, which is expected to grow at a steady pace.

Upcoming Catalysts (preview)

• Q3 2026Launch of new pooled CRISPR screening library targeting epigenetic regulators70% success
• Q4 2026Strategic partnership with a top-10 pharmaceutical company for oncology target discovery40% success
• TBDExpansion into single-cell transcriptome profiling services50% success